Johnson & Johnson coronavirus vaccine trial to resume soon: Washington Post

FILE PHOTO: The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company's listing at the NYSE in New York

(Reuters) - Johnson & Johnson's coronavirus vaccine trial will resume very soon after investigators concluded a participant's illness was unrelated to the vaccine, the Washington Post reported on Friday, citing two people familiar with the matter.

(Reporting by Munsif Vengattil; Editing by Anil D'Silva)